On March 11, Sina Jasim, MD, MPH and co-authors had their paper titled “American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment,” published in “Head & Neck.”
There is a clear increase in the development of systematic treatment options that intend to leverage the molecular landscape of advanced thyroid cancer (ATC). This paper defines ATC and its targeted systematic treatment through a multidisciplinary evidence-based statement.
While using the Delphi method, the statement was formed from the consensus of an expert panel and a literary review. The panel reviewed the molecular level of thyroid oncogenesis and defined the characteristics of ATC. Stating that “all patients with ATC and most patients with incurable radioiodine refractory differentiated thyroid cancer should undergo somatic mutational testing. Next-generation sequencing can reveal targetable mutations and potentially give patients affected by advanced thyroid carcinoma systemic treatment options that can prolong survival. These new innovative approaches are changing the landscape of clinical care for patients with advanced thyroid cancer.”